The finding: Genetically disrupting growth hormone receptors beginning at 12 months of age improved overall survival in male and female mice in a new Aging Cell study. Several measures of metabolic and physical function also improved, particularly in males. The key advance is timing: the intervention began after normal early development, rather than operating from birth.
This is experimental mouse research. It does not demonstrate that people should suppress growth hormone, or that reducing its action extends human lifespan.
Changing how cells receive a hormone signal
Growth hormone helps regulate growth, metabolism and tissue maintenance. It acts by binding to receptors on cells, which then relay instructions inside the cell. One consequence is production of insulin-like growth factor 1, or IGF-1, an important growth-related signal.
The researchers used genetically engineered mice with a system that could disrupt the Ghr receptor gene when activated with tamoxifen. They activated that system at 12 months, a middle-aged stage for laboratory mice, and compared the animals with controls. The longevity cohort contained approximately 30 to 35 mice per group and was followed until natural death. Separate cohorts were examined at 19 or 23 months.
Tamoxifen served as the trigger for an engineered genetic switch. This was not a trial showing that tamoxifen itself is a longevity treatment, and it was not a test of an ordinary hormone-lowering regimen.
In fact, circulating growth hormone increased after receptor disruption, while IGF-1 decreased. The animals became less responsive to growth hormone. Reduced hormone signaling and a lower hormone concentration are different things.
What the survival results show
The comparison of survival curves across the follow-up period was statistically significant in both sexes. Median lifespan, the age by which half the animals had died, rose from 929 to 1,003 days in females, an increase of about 8%. In males it rose from 943 to 1,011 days, about 7%.
The male median difference did not reach conventional statistical significance when tested separately. That does not erase the significant overall survival result, but it matters when interpreting the headline numbers. Evidence for improved survival among the longest-lived animals was also stronger in females; the corresponding male maximum-lifespan analyses were not significant.
End-of-life examinations did not find a significant reduction in fatal tumors or overall disease burden. Longer survival therefore should not be read as proof that every major age-related disease was prevented.
Benefits were selective, with clearer functional changes in males
Male mice became more sensitive to insulin, meaning their bodies responded more effectively to the hormone that helps control blood sugar. Glucose tolerance, a related but different measure of how the body handles a glucose challenge, was not significantly improved.
Males also performed better on measures of grip strength and balance or coordination on a rotating rod after adjustment for lean body mass. Imaging suggested modest preservation of the spongy internal structure of vertebral bone, including higher bone mineral density. These findings concern measured aspects of function and bone structure, not proof of fewer fractures.
The effects were not uniformly beneficial. Fat percentage increased and lean mass percentage decreased. Female mice did not show the same improvements in insulin sensitivity or neuromuscular performance, and a composite frailty score did not significantly improve in either sex.
Why starting in middle age matters
Much of the strongest evidence connecting reduced growth hormone signaling with mouse longevity comes from animals altered throughout life. Such animals develop differently, making it difficult to separate the effects of early growth from the effects of changing aging biology later.
This study addresses that problem by delaying receptor disruption until middle age. It also builds on earlier adult-onset work, rather than being the first experiment to change the pathway after birth. The new result suggests that the opportunity to affect survival in mice remains open after early development. It does not establish how late an intervention can begin, or an equivalent treatment age for humans.
Clues from the liver, not a complete explanation
The team also examined gene activity in individual liver-cell nuclei using single-nucleus RNA sequencing. This method helps distinguish changes in different cell populations that would be obscured in an average across the whole organ.
They found altered immune-cell proportions and sex-specific shifts in liver gene activity. Some male liver-cell expression patterns became more similar to those typically seen in females. These are clues to how disrupted hormone signaling changes tissue biology. They do not establish that a particular gene-expression change caused the longer lifespan.
What this means for people
No people received an intervention in this study. Genetic receptor disruption in one laboratory mouse background does not establish the safety, dose, reversibility or long-term effects of a drug intended to alter the same pathway in humans. Independent replication and carefully designed human research would be needed before clinical claims could follow.
Commercial growth hormone anti-aging claims are not equivalent to this experiment. Giving growth hormone to people, promoting products that stimulate its release, and genetically reducing receptor signaling in mice are different interventions. This paper validates none of those commercial promises and provides no basis for changing prescribed hormone treatment.
The scientific contribution is specific: middle-aged mice remained responsive to an experimental change in growth hormone receptor signaling, with longer overall survival and selective functional benefits. Whether that biology can be translated into safe, useful treatment for people remains unanswered.
Evidence level: Early Research
Study type: Genetic intervention in mice, with lifespan follow-up and molecular analysis
Primary source: Duran-Ortiz S and colleagues. Midlife Growth Hormone Receptor Ablation Extends Healthy Lifespan and Induces Sex-Specific Hepatic Transcriptional Changes at Single-Cell Resolution. Aging Cell, September 2026. DOI: 10.1111/acel.70695.
Image: AI-generated conceptual illustration of mouse research and cell signaling.